SK Biopharmaceuticals Q1 2026: Operating Profit of KRW 89.8B on Strong Cenobamate Sales

Consolidated Q1 revenue KRW 227.9B, operating profit KRW 89.8B, net profit KRW 102.7B
Cenobamate (XCOPRI®) sales KRW 223.9B (98.3% of total), continued growth
U.S. epilepsy market share rose to 6.6% (2025), competitive advantage vs. expiring patents
Global expansion: launched in China (March 2026), NDA submitted in Japan (Sep 2025)
R&D expenses KRW 47.6B (20.9% of revenue), investing in RPT, TPD modalities
Debt ratio 41.7% (improved from 45.0% at year-end 2025), sound financial structure
Ongoing patent infringement lawsuits regarding XCOPRI® generics (Aurobindo, Apotex, MSN)